Literature DB >> 6161964

The transformation of adult but not newborn human lymphocytes by Epstein Barr virus and phytohemagglutinin is inhibited by interferon: the early suppression by T cells of Epstein Barr infection is mediated by interferon.

D A Thorley-Lawson.   

Abstract

In a previous study, it was demonstrated that T cells from adult individuals were able to suppress the transformation of B cells after infection by EBV. In this paper, it is shown that this suppression is mediated by interferon. Thus, the suppression is abrogated by anti-interferon serum and mimicked by human leukocyte interferon. Furthermore, the interferon is released in response to the virus-infected B cell, not the virus alone. The relevance of these results to previous clinical evidence, indicating a role for interferon in recovery from EBV infection, is discussed. Interferon will also suppress the transformation of adult B lymphocytes by the mitogen phytohemagglutinin (PHA). However, interferon at concentrations 2 to 3 orders of magnitude higher was unable to suppress the transformation of neonatal B lymphocytes by either EBV or PHA. These experiments suggest that EBV and PHA induced transformation share a common interferon sensitive step. Lastly, the resistance of newborn lymphocytes to the protective effect of interferon may be an important consideration in the application of interferon as an antiviral or anti-tumor agent.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6161964

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells.

Authors:  Daniel Salamon; Monika Adori; Dorina Ujvari; Liang Wu; Lorand L Kis; Harsha S Madapura; Noemi Nagy; George Klein; Eva Klein
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.

Authors:  Nancy H Gudgeon; Graham S Taylor; Heather M Long; Tracey A Haigh; Alan B Rickinson
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  Evolving principles in immunopathology: interleukin 10 and its relationship to Epstein-Barr virus protein BCRF1.

Authors:  K W Moore; F Rousset; J Banchereau
Journal:  Springer Semin Immunopathol       Date:  1991

4.  The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells.

Authors:  Timothy R Geiger; Jennifer M Martin
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

5.  Epstein-Barr virus recombinants with specifically mutated BCRF1 genes.

Authors:  S Swaminathan; R Hesselton; J Sullivan; E Kieff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Immune function in chronic active Epstein-Barr virus infection.

Authors:  R Kibler; D O Lucas; M J Hicks; B T Poulos; J F Jones
Journal:  J Clin Immunol       Date:  1985-01       Impact factor: 8.317

Review 7.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

8.  Cellular defenses against Toxoplasma gondii in newborns.

Authors:  C B Wilson; J E Haas
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

9.  Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.

Authors:  G R Nemerow; F C Jensen; N R Cooper
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

10.  The EBNA2-related resistance towards alpha interferon (IFN-alpha) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3.

Authors:  K Kanda; T Decker; P Aman; M Wahlström; A von Gabain; B Kallin
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.